TITLE:
Effect of Varenicline on Detrusor Overactivity in Rat Model of Parkinson’s Disease Induced by Intranigral 6-Hydroxydopamine
AUTHORS:
Zeynep Mine Altunay, Fatma Rüyal Tan, Nermin Bölükbaşı, Funda Fatma Bölükbaşı Hatip, Izzettin Hatip-Al-Khatib
KEYWORDS:
Nicotinic Cholinergic Receptors, Overactive Bladder, Varenicline, Parkinson Disease, Alpha7 Nicotinic Cholinergic Receptor Agonists
JOURNAL NAME:
Advances in Parkinson's Disease,
Vol.11 No.1,
February
28,
2022
ABSTRACT: Background: Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by both motor and non-motor symptoms. Bladder dysfunction is the common non-motor symptom of PD, most often presenting with detrusor overactivity (DO). Treatment of DO is currently limited, poorly tolerated and sometimes ineffective. Bladder responses are not only mediated by muscarinic cholinergic receptors (mAChR) but also by nicotinic cholinergic receptors (nAChR). However, nicotinic receptor subtypes and functions in the bladder are not clearly identified. Purpose: This study aimed at investigating the effect of varenicline, an alpha7 full agonist and alpha4beta2/alpha3 partial agonist, on detrusor strips in rat PD model induced by substantia nigra injection of 6-hydroxydopamine. Method: The detrusor activity was studied in an isolated organ bath system. Results: In PD group, the detrusor activity was increased, whereas varenicline decreased the DO. Conclusion: Alpha7 nAChR agonists may have therapeutic potential in treatment of bladder overactivity in PD.